Skip to main content

Table 2 Best overall response by criteria.

From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Criteria

Response/Evaluable

% (95% CI)

PSA

5/22

23 (8–45)

Measurable

0/8

0 (0–31)

Bone disease

1/20

5 (0–25)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us